跳转至内容
Merck

63179

Sigma-Aldrich

3-(马来酰亚胺基)丙酸 N-羟基琥珀酰亚胺酯

≥98.5% (HPLC)

别名:

3-(马来酰亚胺基)丙酸 N-琥珀酰亚胺酯, BMPS, N-琥珀酰亚胺基 3-马来酰亚胺丙酸酯, N-马来酰基-β-丙氨酸 N'-羟基琥珀酰亚胺酯, N-(3-马来酰亚胺丙酰氧基)琥珀酰亚胺

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C11H10N2O6
CAS号:
分子量:
266.21
Beilstein:
1492578
MDL號碼:
分類程式碼代碼:
12352106
PubChem物質ID:
NACRES:
NA.25

品質等級

化驗

≥98.5% (HPLC)

形狀

solid

反應適用性

reagent type: linker

mp

167-171 °C

官能基

NHS ester

儲存溫度

2-8°C

SMILES 字串

O=C1CCC(N1OC(CCN2C(C=CC2=O)=O)=O)=O

InChI

1S/C11H10N2O6/c14-7-1-2-8(15)12(7)6-5-11(18)19-13-9(16)3-4-10(13)17/h1-2H,3-6H2

InChI 密鑰

JKHVDAUOODACDU-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

應用

琥珀酰亚胺基 3-马来酰亚胺丙酸酯 (SMP,BMPS) 用作脂肪族异双功能交联剂试剂。用于诸如酶免疫测定前半抗原与酶交联或荧光底物与肽抗原交联等技术,用于荧光免疫测定。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

S J Xiao et al.
Journal of materials science. Materials in medicine, 8(12), 867-872 (2004-09-07)
Surface modification of acid-pretreated titanium with 3-aminopropyltriethoxylsilane (APTES) in dry toluene resulted in covalently bonded siloxane films with surface coverage that was relatively controllable by regulating the reaction conditions. A hetero-bifunctional cross-linker, N-succinimidyl-3-maleimidopropionate (SMP), reacted with the terminal amino groups
T. Kitagawa
Enzyme Immunoassay, 81-81 (1981)
S Heyse et al.
Protein science : a publication of the Protein Society, 4(12), 2532-2544 (1995-12-01)
A new method is presented for measuring sensitively the interactions between ligands and their membrane-bound receptors in situ using integrated optics, thus avoiding the need for additional labels. Phospholipid bilayers were attached covalently to waveguides by a novel protocol, which
M C Durrieu et al.
Journal of materials science. Materials in medicine, 15(7), 779-786 (2004-09-28)
Ceramics possess osteoconductive properties but exhibit no intrinsic osteoinductive capacity. Consequently, they are unable to induce new bone formation in extra osseous sites. In order to develop bone substitutes with osteogenic properties, one promising approach consists of creating hybrid materials
Mengjie Rui et al.
International journal of nanomedicine, 12, 217-237 (2017-01-25)
The development of drug resistance in cancer cells is one of the major obstacles to achieving effective chemotherapy. We hypothesized that the combination of a doxorubicin (Dox) prodrug and microRNA (miR)21 inhibitor might show synergistic antitumor effects on drug-resistant breast

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门